Polymers of fluorinated and hydrophilic monomers
First Claim
Patent Images
1. An implantable device having a biocompatible coating thereon, wherein the biocompatible coating comprises a polymer blend comprising a biocompatible polymer that comprises fluorinated monomers and at least one other biocompatible polymer,wherein the biocompatible polymer that comprises fluorinated monomers has a structure of formula I:
- where m, n and o are integers and all above zero, and wherein the biocompatible polymer that comprises fluorinated monomers is generated by direct polymerization of the fluorinated monomers and the hydrophilic monomers.
0 Assignments
0 Petitions
Accused Products
Abstract
A polymer blend that contains a polymer of fluorinated monomers and another biocompatible polymer. The polymer blend can form a coating on a medical device. The medical device can be used for treat, prevent or ameliorate a medical condition.
512 Citations
8 Claims
-
1. An implantable device having a biocompatible coating thereon, wherein the biocompatible coating comprises a polymer blend comprising a biocompatible polymer that comprises fluorinated monomers and at least one other biocompatible polymer,
wherein the biocompatible polymer that comprises fluorinated monomers has a structure of formula I: -
where m, n and o are integers and all above zero, and wherein the biocompatible polymer that comprises fluorinated monomers is generated by direct polymerization of the fluorinated monomers and the hydrophilic monomers. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
5. The implantable device of claim 1 which is a drug-delivery stent, wherein the coating further comprises a bioactive agent.
-
6. The implantable device of claim 4 which is a drug-delivery stent, wherein the coating further comprises a bioactive agent.
-
7. The implantable device of claim 5, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and a combination thereof.
-
8. The implantable device drug delivery stent of claim 6, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-0-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and a combination thereof.
Specification